Document Detail

Effects of weekly administration of pegylated recombinant human OB protein on appetite profile and energy metabolism in obese men.
MedLine Citation:
PMID:  11566639     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Results of leptin administration in mice, rats, and humans provide a rationale for therapeutic augmentation of circulating leptin (OB protein) concentrations in obese humans; this may reduce food intake, increase metabolic rate, and lower body mass. OBJECTIVE: We assessed the effects of weekly subcutaneous pegylated polyethylene glycol (PEG)-OB protein administration on appetite and energy metabolism in obese men. DESIGN: We performed a randomized, double-blind, placebo-controlled trial in 30 obese men [body mass index (in kg/m(2)): 34.2 +/- 3.6; age: 44.7 +/- 7 y]. Subjects received 20 mg PEG-OB protein/wk for 12 wk while limiting their energy intake to 2.1 MJ/d. RESULTS: During treatment, appetite and hunger before breakfast decreased and remained lower in the PEG-OB-protein group, whereas they increased and remained higher in the placebo group (P < 0.0001). During treatment, hunger decreased in the PEG-OB-protein group (P < 0.05) and cognitive restraint increased in the placebo group (P < 0.0001). Neither appetite nor food intake changed significantly during the ad libitum evening meal. Under energy balance conditions in the respiration chamber, appetite at the end of treatment was not significantly different from baseline despite similar, significant reductions in 24-h energy intake, energy expenditure, sleeping metabolic rate, body mass, fat mass, and fat-free mass (P < 0.01 for all) in both groups. CONCLUSION: Treatment with PEG-OB protein modified subjective appetite at a dosage that produced no changes in body composition, energy expenditure, or body mass loss relative to placebo treatment, suggesting that PEG-OB protein has central rather than peripheral biological activity in obese men.
M S Westerterp-Plantenga; W H Saris; C J Hukshorn; L A Campfield
Related Documents :
23334049 - Fumonisin b1: a neurotoxic mycotoxin / fumonizin b1: neurotoksični mikotoksin.
20390979 - Parents as health promoters: a theory of planned behavior perspective on the prevention...
9723619 - The stomach is a source of leptin.
19528979 - Individual differences in the neurophysiology of reward and the obesity epidemic.
18715519 - Appetitive traits and child obesity: measurement, origins and implications for interven...
19461159 - Nesfatin-1: an overview and future clinical application.
2394509 - Food temperature and gastric cancer.
17071889 - Estimating source coefficients for phosphorus site indices.
23638049 - Food access and diet quality are associated with quality of life outcomes among hiv-inf...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The American journal of clinical nutrition     Volume:  74     ISSN:  0002-9165     ISO Abbreviation:  Am. J. Clin. Nutr.     Publication Date:  2001 Oct 
Date Detail:
Created Date:  2001-09-21     Completed Date:  2001-10-11     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0376027     Medline TA:  Am J Clin Nutr     Country:  United States    
Other Details:
Languages:  eng     Pagination:  426-34     Citation Subset:  AIM; IM    
Department of Human Biology, Maastricht University, Maastricht, Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Appetite / drug effects*
Body Mass Index
Double-Blind Method
Eating / drug effects
Energy Metabolism / drug effects*
Leptin / pharmacology*
Middle Aged
Obesity / metabolism*
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Flavonoids: a review of probable mechanisms of action and potential applications.
Next Document:  Sex and hormonal status influence plasma lipid responses to psyllium.